A novel phase Ib clinical trial of adjuvant p53 peptide-loaded DC cells demonstrated that the DC–p53 vaccine triggered a p53-specific immune response in 11 patients with head and neck squamous cell carcinoma, out of the 16 patients treated (Schuler et al., 2014). The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.